Sinclair IS Pharma plc Acquires Atlean® from GSK Stiefel

Posted: 31st January 2014 08:40

Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair" or "the Group"), the international specialty pharmaceutical company, announces that it has acquired Atlean®, a dermal filler, from Stiefel the dermatology business of GSK for an undisclosed cash consideration. Atlean® combines a collagen stimulator and hyaluronic acid filler particularly for the treatment of the lower face and complements Sinclair's existing facial aesthetic brands, Sculptra® and Perfectha®. This acquisition enables Sinclair to add a collagen stimulator to market alongside Perfectha® in its international facial aesthetics business focused on Asia-Pacific, LATAM and Russia. In Europe Atlean® will provide Sinclair's aesthetic sales forces with a yet more comprehensive product range.
Atlean® has not been actively marketed in Europe since 2012 and requires the European CE Mark registration to be regained which is expected to take around 9-12 months. First revenues are therefore expected in H2 FY2015.

Related articles



Subscribe to our newsletter

Sign up here and get the latest news and updates delivered directly to your inbox

You can unsubscribe at any time